Genetron Health Reiterates Full Year 2021 Revenue Guidance
January 10 2022 - 6:00AM
Genetron Holdings Limited (“Genetron Health” or the “Company”,
Nasdaq: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today reiterated its full year 2021 revenue guidance. The Company
expects full year 2021 revenue to be around RMB 530 million,
representing approximately 25% growth over the Company’s full year
2020 revenue.
“We are pleased with our accomplishments in 2021 amid a
challenging operating environment that continues to be heavily
impacted by the COVID-19 pandemic,” said Mr. Sizhen Wang,
co-founder and CEO of Genetron Health. “Throughout 2021 we
experienced strong growth led by our in-hospital IVD sales,
advanced our early screening registrational strategy for
hepatocellular carcinoma, developed a multi-omics blood-based CRC
early screening assay, established partnerships with AstraZeneca
R&D China and Fosun Pharma to develop and commercialize MRD
products, and expanded the body of clinical evidence and
publications that reinforce and support the clinical value of our
tests. These accomplishments have positioned Genetron favorably to
drive meaningful growth in the coming years.”
The Company will discuss its fourth quarter and full year 2021
results during its earnings call in March.
About Genetron Holdings LimitedGenetron
Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH)
is a leading precision oncology platform company in China that
specializes in cancer molecular profiling and harnesses advanced
technologies in molecular biology and data science to transform
cancer treatment. The Company has developed a comprehensive
oncology portfolio that covers the entire spectrum of cancer
management, addressing needs and challenges from early screening,
diagnosis, and treatment recommendations, as well as continuous
disease monitoring and care. Genetron Health also partners with
global biopharmaceutical companies and offers customized services
and products. For more information, please visit
https://ir.genetronhealth.com/.
Safe Harbor StatementThis press release
contains forward-looking statements. These statements are made
under the “safe harbor” provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Statements that are not historical
facts, including statements about the Company’s beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Investor Relations ContactUS:Hoki LukHead of
Investor RelationsEmail: hluk@genetronhealth.us Phone: +1
(408) 891-9255
Philip Trip TaylorVice President | Gilmartin GroupEmail:
ir@genetronhealth.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024